The FIPO23 trial: First-in-human phase I/II study of XON7 in advanced solids tumors. ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results